Connolly Anne, Rogers Paul, Taylor David
Pharmacy Department, Maudsley Hospital, London, UK.
J Psychopharmacol. 2007 Mar;21(2):191-7. doi: 10.1177/0269881107065899.
A number of studies have shown qualitative and quantitative differences in prescribing of antipsychotics according to patient ethnicity. Black patients tend, for example, to be prescribed higher doses of antipsychotics than whites. Few studies have controlled for other factors which may influence prescribing practice and confound results. This study sought to determine whether or not ethnicity was associated with antipsychotic polypharmacy, high dosage and antipsychotic costs before and after adjustment for potential confounding. We approached inpatients on acute general psychiatry wards at the Maudsley, Bethlem and Lambeth hospitals in south east London. Prescription details were noted. Subjects were interviewed and social and clinical details were recorded. In all, data on 23 potential confounders were collected.A total of 210 patients were approached of whom 153 agreed to take part. Of the 23 potential confounders, only use of English as a first language and duration of illness differed significantly between blacks and whites. Categorical findings were adjusted for these factors and other potential confounders such as age and gender. Total antipsychotic daily dose was 82.2% of licensed maximum in blacks, and 77.2% in whites (p=0.48). Antipsychotic polypharmacy was seen in 23.2% of blacks and 16.9% of whites (adjusted odds ratio (OR) 1.11; 95% CI, 0.45-2.75). High dose (> 100% of maximum dose) antipsychotic regimens were prescribed to 15.9% of blacks and 16.9% of whites (adjusted OR, 0.71: 95% CI, 0.27-1.90). Mean monthly cost of treatment was significantly higher in blacks than whites (182.79 vs 143.08 British pound; p=0.02; adjusted OR (> 150 British pound/month), 2.45: 95% CI, 1.19-5.08). Prescribing quality was similar for blacks and whites. Black ethnicity was associated with significantly higher mean monthly medication costs.
多项研究表明,根据患者种族不同,抗精神病药物的处方在定性和定量方面存在差异。例如,黑人患者往往比白人患者服用更高剂量的抗精神病药物。很少有研究对可能影响处方行为并混淆结果的其他因素进行控制。本研究旨在确定在对潜在混杂因素进行调整前后,种族是否与抗精神病药物联合使用、高剂量使用及抗精神病药物费用相关。我们走访了伦敦东南部莫兹利医院、贝斯勒姆医院和兰贝斯医院急性普通精神科病房的住院患者,记录了处方细节,并对受试者进行访谈,记录其社会和临床细节。总共收集了23个潜在混杂因素的数据。共接触了210名患者,其中153名同意参与。在23个潜在混杂因素中,只有以英语为第一语言的情况和病程在黑人和白人之间存在显著差异。对这些因素以及年龄和性别等其他潜在混杂因素进行了分类结果调整。黑人的抗精神病药物每日总剂量为许可最大剂量的82.2%,白人为77.2%(p = 0.48)。23.2%的黑人患者和16.9%的白人患者使用了抗精神病药物联合治疗(调整后的优势比(OR)为1.11;95%置信区间,0.45 - 2.75)。15.9%的黑人患者和16.9%的白人患者接受了高剂量(>最大剂量的100%)抗精神病药物治疗方案(调整后的OR为0.71:95%置信区间,0.27 - 1.90)。黑人的平均每月治疗费用显著高于白人(182.79英镑对143.08英镑;p = 0.02;调整后的OR(>150英镑/月)为2.45:95%置信区间,1.19 - 5.08)。黑人和白人的处方质量相似。黑人种族与显著更高的平均每月药物费用相关。